Search

Your search keyword '"Ciolli, S"' showing total 180 results
Start Over Author "Ciolli, S"
180 results on '"Ciolli, S"'

3. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Author

Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., Del Poeta G., Tedeschi, A, Frustaci, A, Mauro, F, Chiarenza, A, Coscia, M, Ciolli, S, Reda, G, Laurenti, L, Varettoni, M, Murru, R, Barate, C, Sportoletti, P, Greco, A, Borella, C, Rossi, V, Deodato, M, Biagi, A, Zamprogna, G, Pelle, A, Lapietra, G, Vitale, C, Morelli, F, Cassin, R, Fresa, A, Cavalloni, C, Postorino, M, Ielo, C, Cairoli, R, Di Raimondo, F, Montillo, M, Del Poeta, G, Tedeschi A., Frustaci A. M., Mauro F. R., Chiarenza A., Coscia M., Ciolli S., Reda G., Laurenti L., Varettoni M., Murru R., Barate C., Sportoletti P., Greco A., Borella C., Rossi V., Deodato M., Biagi A., Zamprogna G., Pelle A. C., Lapietra G., Vitale C., Morelli F., Cassin R., Fresa A., Cavalloni C., Postorino M., Ielo C., Cairoli R., Di Raimondo F., Montillo M., and Del Poeta G.

Abstract

Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect drug management. We confirmed the role of CIRS . 6 as a predictor of a poorer progression- and event-free survival (PFS, EFS). The presence of a severe comorbidity was significantly associated with permanent dose reductions (PDRs), not translating into worse outcomes. As expected, del(17p) and/or TP53mut and previous therapies affected PFS, EFS, and overall survival. No study so far has analyzed the influence of concomitant medications and CYP3A inhibitors with ibrutinib. In our series, these factors had no impact, although CYP3A4 inhibitors use correlated with Cox regression analysis, with an increased risk of PDR. Despite the limitation of its retrospective nature, this large study confirmed the role of ECOG-PS as the most accurate predictor of ibrutinib feasibility and outcomes, and importantly, neutropenia emerged as a relevant tool influencing patients’ vulnerability. Although CIRS > 6 retained a significant impact on PFS and EFS, its value should be confirmed by prospective studies.

Published
2021

5. Tsunami evacuation times and routes to safe zones: a GIS-based approach to tsunami evacuation planning on the island of Stromboli, Italy

Author

Bonilauri, EM, Harris, AJL, Morin, J, Ripepe, M, Mangione, D, Lacanna, G, Ciolli, S, Cusolito, M, Deguy, P, Laboratoire Magmas et Volcans (LMV), Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Recherche pour le Développement et la société-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Observatoire de Physique du Globe de Clermont-Ferrand (OPGC), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Laboratorio di Geofisica Sperimentale, Università degli Studi di Firenze, Florence, Dipartimento della Protezione Civile, Rome, Lipari town council, Lipari, Aeolian Islands, Dipartimento di Scienze della Terra, Università degli Studi di Firenze, Florence, ANR-10-LABX-0006,CLERVOLC,Clermont-Ferrand centre for research on volcanism(2010), ANR-16-IDEX-0001,CAP 20-25,CAP 20-25(2016), Università degli Studi di Firenze = University of Florence (UniFI), Bonilauri, EM [0000-0003-4254-8835], and Apollo - University of Cambridge Repository

Subjects
Evacuation maps, 37 Earth Sciences, Evacuation modelling, Stromboli, Volcanic island hazard, Volcanogenic tsunami, Environmental protection, Disasters and engineering, Clinical Research, TD169-171.8, TA495, [SDU.STU.VO]Sciences of the Universe [physics]/Earth Sciences/Volcanology, 3704 Geoinformatics
Abstract

Funder: IDEX-ISITE initiative16-IDEX-0001 (CAP 20-25), While a landslide at the volcanic island of Stromboli (Aeolian Islands, Italy) in December 2002 created a tsunami with a run-up of 10.9 m, two paroxysmal eruptions in the summer of 2019 caused a tsunami with an amplitude of 40 to 20 cm. All three events required rapid, spontaneous emergency evacuations of the beach zone as the time between tsunami generation and impact is around 4 min. These conditions thus require a special consideration of the issue of evacuation capabilities on the island in the event of a volcanogenic tsunami. The purpose of this paper is thus to (i) determine pedestrian evacuation times from high-risk coastal areas to safe zones, (ii) to assess building evacuation ease, and (iii) determine emergency evacuation plans (for buildings and coastal zones). For this purpose, we created a GIS-based risk analysis/mapping tool that also allowed macroscopic evacuation modelling. In our case, the high-risk zone to be evacuated involves an area extending to 10 m a.s.l. and involving 123 individual buildings over an area of 0.18 km2. The results show that 33% of the buildings can be evacuated in 4 min, and that a 10-min warning time is required for a complete and well-distributed evacuation whereby the population is evenly distributed between all evacuation exits to avoid the potential for congestion. Initial interviews of residents in the at-risk zone reveal a high level of awareness and a desire for personalized evacuation scenarios.

Published
2021

7. EFFICACY AND DISCONTINUATION RATE OF IBRUTINIB IN TREATMENT NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH TP53 ABNORMALITIES. A REAL‐LIFE CAMPUS CLL STUDY

Author

Visentin, A., primary, Mauro, F. R., additional, Cibien, F., additional, Vitale, C., additional, Reda, G., additional, Fresa, A., additional, Ciolli, S., additional, Pietrasanta, D., additional, Marchetti, M., additional, Murru, R., additional, Gentile, M., additional, Rigolin, G. M., additional, Quaglia, F. M., additional, Scarfò, L., additional, Sportoletti, P., additional, Pravato, S., additional, Romano Gargarella, L., additional, Facco, M., additional, Piazza, F., additional, Coscia, M., additional, Laurenti, L., additional, Molica, S., additional, Pizzolo, G., additional, Foà, R., additional, Cuneo, A., additional, and Trentim, L., additional

Published
2021
Full Text
View/download PDF

8. Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Author

Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., De Paoli, L., Murru, R., Gentile, M., Rigolin, G. M., Levato, L., Giordano, A., Del Poeta, G., Stelitano, C., Ielo, C., Noto, A., Guarente, V., Molica, S., Coscia, M., Tedeschi, A., Gaidano, G., Cuneo, A., Foa, R., Martelli, M., Girmenia, C., Gentile, G., Trentin, L., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Molica S., Tedeschi A., Foa R., Martelli M., Gentile G., Mauro, F. R., Giannarelli, D., Visentin, A., Reda, G., Sportoletti, P., Frustaci, A. M., Chiarenza, A., Ciolli, S., Vitale, C., Laurenti, L., De Paoli, L., Murru, R., Gentile, M., Rigolin, G. M., Levato, L., Giordano, A., Del Poeta, G., Stelitano, C., Ielo, C., Noto, A., Guarente, V., Molica, S., Coscia, M., Tedeschi, A., Gaidano, G., Cuneo, A., Foa, R., Martelli, M., Girmenia, C., Gentile, G., Trentin, L., Laurenti L. (ORCID:0000-0002-8327-1396), Gentile M., Molica S., Tedeschi A., Foa R., Martelli M., and Gentile G.

Abstract

Ibrutinib represents extraordinary progress in the treatment of chronic lymphocytic leukemia (CLL). However, treatment-related adverse events limit the benefit of this agent. This obser-vational, multicenter study focused on the incidence, risk factors, and prognostic impact of infections in 494 patients with CLL treated with an ibrutinib-based treatment. Ibrutinib was given to 89 (18%) previously untreated patients (combined with rituximab, 24) and 405 (82%) relapsed/refractory patients. Pneumonia (PN), grade ≥3 non-opportunistic infections (NOI), and opportunistic infections (OI) were recorded in 32% of patients with an overall incidence rate per 100 person-year of 15.3% (PN, 10%; NOI, 3.3%; OI, 2%). Infections were the reason for the permanent discontinuation of ibrutinib in 9% of patients. Patients who experienced pneumonia or a severe infection showed a significantly inferior survival than those who were infection-free (p < 0.0001). A scoring system based on the three factors associated with a significant and independent impact on infections—PN or severe infection in the year before starting ibrutinib, chronic obstructive pulmonary disease, ≥2 prior treatments—identified patients with a two-to threefold increase in the rate of infections. In conclusion, the results of this study highlight the adverse impact of infectious events on the outcomes of CLL patients treated with ibrutinib.

Published
2021

9. Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape

Author

Morelli, F, Innocenti, I, Autore, F, Fresa, F, Tomasso, A, Piciocchi, A, Frustaci, Am, Trentin, L, Mauro, Fr, Schiattone, L, Visentin, A, Del Poeta, G, Reda, G, Rigolin, Gm, Ibatici, A, Ciolli, S, Vitale, C, Sportoletti, P, Murru, R, Levato, L, Gentile, M, D’Arena, G, Coscia, M, Villa, Mr, Fontana, R, Efremov, D, Tedeschi, A, Scarfò, L, Cuneo, A, Foà, R, and Laurenti, L

Published
2020

11. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients

Author

Visani, G, Bernasconi, P, Boni, M, Castoldi, GL, Ciolli, S, Clavio, M, Cox, MC, Cuneo, A, Del Poeta, G, Dini, D, Falzetti, D, Fanin, R, Gobbi, M, Isidori, A, Leoni, F, Liso, V, Malagola, M, Martinelli, G, Mecucci, C, Piccaluga, PP, Petti, MC, Rondelli, R, Russo, D, Sessarego, M, Specchia, G, Testoni, N, Torelli, G, Mandelli, F, and Tura, S

Published
2001
Full Text
View/download PDF

17. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Author

Cuneo, A, Follows, G, Rigolin, GM, Piciocchi, A, Tedeschi, A, Trentin, L, Perez, AM, Coscia, M, Laurenti, L, Musuraca, G, Farina, L, Delgado, AR, Orlandi, EM, Galieni, P, Mauro, FR, Visco, C, Amendola, A, Billio, A, Marasca, R, Chiarenza, A, Meneghini, V, Ilariucci, F, Marchetti, M, Molica, S, Re, F, Gaidano, G, Gonzalez, M, Forconi, F, Ciolli, S, Cortelezzi, A, Montillo, M, Smolej, L, Schuh, A, Eyre, TA, Kennedy, B, Bowles, KM, Vignetti, M, de la Seam, J, Moreno, C, Foa, R, Ghia, P, GIMEMA, European Res Initiative CLL ERIC, and UK CLL Forum

Abstract

We performed an observational study on the efficacy of ben-damustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. The presence of del(17p), unmutated IGHV and advanced stage were associated with a shorter PFS at multivariate analysis. The median time-to-next treatment was 31.3 months. Front-line treatment with a chemoimmunotherapy regimen was the only predictive factor for a shorter time to next treatment at multivariate analysis. The median overall survival (OS) was 74.5 months. Advanced disease stage (i.e. Rai stage III-IV or Binet stage C) and resistant disease were the only parameters significantly associated with a shorter OS. Grade 3-5 infections were recorded in 6.3% of patients. A matched-adjusted indirect comparison with ibrutinib given second-line within Named Patient Programs in the United Kingdom and in Italy was carried out with OS as objective end point. When restricting the analysis to patients with intact 17p who had received chemoimmunotherapy in first line, there was no difference in OS between patients treated with ibrutinib (63% alive at 36 months) and patients treated with BR (74.4% alive at 36 months). BR is an efficacious first salvage regimen in CLL in a real-life population, including the elderly and unfit patients. BR and ibrutinib may be equally effective in terms of OS when used as first salvage treatment in patients without 17p deletion. (Registered at clinicaltrials.gov identifier: 02491398)

Published
2018

18. PS1152 THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE

Author

Innocenti, I., primary, Morelli, F., additional, Autore, F., additional, Piciocchi, A., additional, Frustaci, A., additional, Mauro, F.R., additional, Schiattone, L., additional, Trentin, L., additional, Poeta, G. Del, additional, Reda, G., additional, Rigolin, G.M., additional, Ibatici, A., additional, Ciolli, S., additional, Coscia, M., additional, Sportoletti, P., additional, Murru, R., additional, Levato, L., additional, Gentile, M., additional, D’Arena, G., additional, Villa, M.R., additional, Fontana, R., additional, Tedeschi, A., additional, Scarfò, L., additional, Cuneo, A., additional, Foà, R., additional, and Laurenti, L., additional

Published
2019
Full Text
View/download PDF

22. MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)

Author

Scarfo, L, Quaresmini, G, Mauro, Fr, Orlandi, E, Reda, G, Laurenti, L, Coscia, Marta, Ambrosetti, A, Murru, R, Trentin, L, Guelill, A, Visco, C, Morabito, F, Frustaci, A, Ciolli, S, Rossini, F, Cuneo, A, Gozzetti, A, Scortechini, I, Pane, F, Zinzani, Pl, Ferrara, F, Mannina, D, Marasca, R, Pierri, I, Specchia, G, Chiarenza, A, Zallio, F, Molica, S, De Paoli, L, Torreggiani, A, Brugiatelli, M, Semenzato, G, Innocenti, I, Picardi, P, Pizzolo, G, Foa, R, Rambaldi, A, and Ghia, P.

Published
2015

23. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Author

Foà, R, Del Giudice, I, Cuneo, Antonio, Del Poeta, G, Ciolli, S, Di Raimondo, F, Lauria, F, Cencini, E, Rigolin, Gian Matteo, Cortelezzi, A, Nobile, F, Callea, V, Brugiatelli, M, Massaia, M, Molica, S, Trentin, L, Rizzi, R, Specchia, G, Di Serio, F, Orsucci, L, Ambrosetti, A, Montillo, M, Luigi Zinzani, P, Ferrara, F, Morabito, F, Angela Mura, M, Soriani, S, Peragine, N, Tavolaro, S, Bonina, S, Marinelli, M, Stefania De Propris, M, Della Starza, I, Piciocchi, A, Alietti, A, Runggaldier, Ej, Gamba, E, Romana Mauro, F, Chiaretti, S, Guarini, A., R. Foà, I. D. Giudice, A. Cuneo, G. D. Poeta, S. Ciolli, F. D. Raimondo, F. Lauria, E. Cencini, G. M. Rigolin, A. Cortelezzi, F. Nobile, V. Callea, M. Brugiatelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, G. Specchia, F. D. Serio, L. Orsucci, A. Ambrosetti, M. Montillo, P. L. Zinzani, F. Ferrara, F. Morabito, M. A. Mura, S. Soriani, N. Peragine, S. Tavolaro, S. Bonina, M. Marinelli, M. S. De, I. D. Starza, A. Piciocchi, A. Alietti, E. J. Runggaldier, E. Gamba, F. R. Mauro, S. Chiaretti, and A. Guarini

Subjects
Male, Murine-Derived, drug therapy/pathology, Male, Survival Analysis, Treatment Outcome, Antibodies, Disease-Free Survival, Drug Administration Schedule, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, 80 and over, 80 and over, Antibodie, Humans, therapeutic use, Chlorambucil, Chronic, Aged, Aged, 80 and over, Aged, Aged, Leukemia, Chlorambucil, Female, Induction Chemotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Survival Analysis, Treatment Outcome, Hematology, B-Cell, Lymphocytic, CLL, chlorambucil, administration /&/ dosage, Antineoplastic Combined Chemotherapy Protocol, administration /&/ dosage, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Induction Chemotherapy, Leukemia, Settore MED/15 - Malattie del Sangue
Abstract

In a phase II trial, we evaluated chlorambucil and rituximab (CLB-R) as first-line induction treatment with or without R as maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28-day cycles of CLB (8 mg/m(2) /day, days 1-7) and R (day 1 of cycle 3, 375 mg/m(2) ; cycles 4-8, 500 mg/m(2) ). Responders were randomized to 12 8-week doses of R (375 mg/m(2) ) or observation. As per intention-to-treat analysis, 82.4\% (95\% CI, 74.25-90.46\%) of 85 patients achieved an overall response (OR), 16.5\% a complete response (CR), 2.4\% a CR with incomplete bone marrow recovery. The OR was similar across Binet stages (A 86.4\%, B 81.6\%, and C 78.6\%) and age categories (60-64 years, 92.3\%; 65-69, 85.2\%; 70-74, 75.0\%; ≥75, 81.0\%). CLB-R was well tolerated. After a median follow-up of 34.2 months, the median progression-free survival (PFS) was 34.7 months (95\% CI, 33.1-39.5). TP53 abnormalities, complex karyotype, and low CD20 gene expression predicted lack of response; SF3B1 mutation and BIRC3 disruption low CR rates. IGHV mutations significantly predicted PFS. R maintenance tended towards a better PFS than observation and was safe and most beneficial for patients in partial response and for unmutated IGHV cases. CLB-R represents a promising option for elderly CLL patients.

Published
2014

24. Bendamustine in combination with rituximab as first line therapy for patients with chronic lymphocytic leukemia (cll): a retrospective real practice italian multicentre study

Author

Gentile, M, Ciolli, S, Molica, S, Di Renzo, N, Selleri, Carmine, Villa, Mr, De Paolis, Mr, Scortechini, I, Giannotta, A, Minoia, C, Boncompagni, R, Bonanno, V, Levato, L, Musso, M, Mastrullo, L, Melpignano, A, Murru, R, Angelucci, E, Caparrotti, G, Guarini, A, Pinto, A, Ferrara, F, Zinzani, P, and Morabito, F. .

Published
2014

25. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

Author

Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Vannata, Barbara, Efremov, Dg, Ciolli, S, Del Poeta, G, Mauro, Fr, Cortelezzi, A, Borza, Pa, Ghio, F, Mondello, P, Murru, R, Gozzetti, A, Cariccio, Mr, Piccirillo, Nicola, Boncompagni, R, Cantonetti, M, Principe, Mi, Reda, G, Bongarzoni, Velia, Cervetti, G, Pitini, V, Foa, Robin, Sica, Simona, D'Arena, G., Laurenti L (ORCID:0000-0002-8327-1396), Innocenti I, Autore F, Vannata B, Piccirillo N (ORCID:0000-0002-1688-1987), Sica S (ORCID:0000-0003-2426-3465), Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Vannata, Barbara, Efremov, Dg, Ciolli, S, Del Poeta, G, Mauro, Fr, Cortelezzi, A, Borza, Pa, Ghio, F, Mondello, P, Murru, R, Gozzetti, A, Cariccio, Mr, Piccirillo, Nicola, Boncompagni, R, Cantonetti, M, Principe, Mi, Reda, G, Bongarzoni, Velia, Cervetti, G, Pitini, V, Foa, Robin, Sica, Simona, D'Arena, G., Laurenti L (ORCID:0000-0002-8327-1396), Innocenti I, Autore F, Vannata B, Piccirillo N (ORCID:0000-0002-1688-1987), and Sica S (ORCID:0000-0003-2426-3465)

Abstract

X

Published
2015

26. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

Author

Cortelezzi, A, Gritti, G, Laurenti, L, Cuneo, Antonio, Ciolli, S, Di Renzo, N, Musto, P, Mauro, Fr, Cascavilla, N, Falchi, L, Zallio, F, Callea, V, Maura, F, Martinelli, S, Piciocchi, A, Reda, G, Foà, R, and on behalf of the GIMEMA Chronic Lymphoproliferative Disorders Working Party

Subjects
Chronic lymphocytic leukaemia, Alemtuzumab, Infection, Monoclonal antibodies
Published
2012

29. A PHASE II STUDY OF CHLORAMBUCIL+RITUXIMAB (CLB-R) FOLLOWED BY R MAINTENANCE VS OBSERVATION IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INDUCTION PHASE RESULTS

Author

Foa, R., Alietti, A., Guarini, A., Ciolli, S., Di Raimondo, F., Del Poeta, G., Lauria, F., Forconi, F., Antonio Cuneo, Cortellezzi, A., Nobile, F., Callea, V., Brugiatelli, M., Massaia, M., Molica, S., Trentin, L., Rizzi, R., Specchia, G., Orsucci, L., Ambrosetti, A., Montillo, M., Zinzani, L., Ferrara, F., Morabito, F., Marco Mura, Soriani, S., Santangelo, S., Marinelli, M., Propris, M., and Runggaldier, J.

Published
2011

30. Will Molecular Biology Contribute to Refine Prognosis and to Select Treatment?

Author

Zaccaria, A, Martinelli, G, Buzzi, M, Farabegoli, P, Saglio, G, Guerrasio, A, Bernabei, P, Santini, V, Pellicci, P, Mencarelli, A, Coco, F, Diverio, D, Rambaldi, A, Santoro, A, Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
INTERFERON, CHRONIC MYELOID LEUKEMIA, Cancer Research, PROGNOSIS, biology, Settore MED/06 - Oncologia Medica, business.industry, MOLECULAR BIOLOGY, Breakpoint, Transcript analysis, Hematology, HindIII, Bioinformatics, Restriction site, Text mining, Oncology, Risk index, biology.protein, Medicine, In patient, business, Settore MED/15 - Malattie del Sangue, Southern blot
Abstract

The possible prognostic value of the position of the breakpoint within the M-BCR in patients with Phl+ CML is still being debated. We analyzed the DNA rearrangements and the transcript types of 244 patients and tried to correlate the data obtained with prognostic features, defined according to Sokal's risk index, and with chronic phase and/or survival duration. The exact location of the breakpoint, either 5' or 3' to the Hind III restriction site within the M-BCR was identified. Moreover, the exact M-BCR subregion was also identified. As a whole, 150 pts were rearranged in the 5' part and 94 in the 3' part of the M-BCR. No correlation was observed between the site of rearrangement on the one hand and the Sokal's prognostic index and survival, on the other. Transcript analysis was performed in 130 patients; 59 carried an a2b2 and 69 an a2b3 pattern. Two patients carried both transcripts. Of the patients rearranged in the 5' area, according to Southern blotting, 29.2% showed an a2b3 transcript. Therefore, R...

Published
1993

31. IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI O) INDEPENDENT OF UNMUTATED STATUS

Author

Forconi, F, Cencini, E, Rossi, D, Sozzi, E, Bomben, R, Marasca, R, Coscia, M, Massaia, M, Veronese, S, Tedeschi, A, Montillo, M, Fazzi, R, Petrini, M, Ciolli, S, Bosi, A, Dottori, R, Pirrotta, M, Carernani, A, DEL POETA, G, DEL GIUDICE, I, Santangelo, S, Laurenti, L, Efremov, D, Trentin, Livio, Bertoni, F, Gattei, V, Gaidano, G, and Lauria, F.

Published
2010

32. IGHV1-69/D3-16/J3 subset 6 is associate with indolent disease course of early stage CLL (RAI 0) independent of unmutated status

Author

Forconi, F., Cencini, E., Rossi, D., Sozzi, E., Bomben, R., Marasca, R., Coscia, Marta, Massaia, Massimo, Veronese, S., Tedeschi, A., Montillo, M., Fazzi, R., Petrini, M., Ciolli, S., Bosi, A., Dottori, R., Pirrotta, M., Caremani, A., Del Poeta, G., Del Giudice, I., Santangelo, S., Laurenti, L., Efremov, D., Trentin, L., Bertoni, F., Gattei, V., Gaidano, G., and Lauria, F.

Published
2010

33. IGHV1-69/D3-16/J3 subset 6 is associated with indolent disease course of early stage CLL (RAI 0), which is independent of unmutated IGH status

Author

Forconi, F, Sozzi, E, Rossi, D, Cencini, E, Sicuranza, A, Marasca, R, Coscia, M, Massaia, M, Veronese, S, Tedeschi, A, Montillo, M, Fazzi, R, Petrini, M, Ciolli, S, Bosi, A, Dottori, R, Algeri, R, Pirrotta, Mt, Caremani, A, Bomben, R, Del Poeta, G, DEL GIUDICE, Ilaria, Santangelo, S, Laurenti, L, Efremov, D, Trentin, L, Bertoni, F, Gattei, V, Gaidano, G, and Lauria, F.

Published
2010

34. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Author

Cuneo, A, Marchetti, M, Barosi, G, Billio, A, Brugiatelli, M, Ciolli, S, Laurenti, Luca, Mauro, Fr, Molica, S, Montillo, M, Zinzani, P, Tura, S., Laurenti, Luca (ORCID:0000-0002-8327-1396), Cuneo, A, Marchetti, M, Barosi, G, Billio, A, Brugiatelli, M, Ciolli, S, Laurenti, Luca, Mauro, Fr, Molica, S, Montillo, M, Zinzani, P, Tura, S., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.

Published
2014

36. Submicroscopic deletions in 5q- associated malignancies

Author

Crescenzi, Barbara, LA STARZA, Roberta, Romoli, Silvia, Beacci, Donatella, Matteucci, Caterina, Barba, Gianluca, Aventin, A., Marynen, P., Ciolli, S., Nozzoli, C., Martelli, Massimo Fabrizio, and Mecucci, Cristina

Published
2004

39. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience

Author

Laurenti, Luca, Tarnani, Michela, Nichele, I, Ciolli, S, Cortelezzi, A, Forconi, F, Rossi, D, Mauro, Fr, D'Arena, G, Del Poeta, G, Montanaro, M, Morabito, F, Musolino, C, Callea, V, Falchi, L, Tedeschi, A, Ambrosetti, A, Gaidano, G, Leone, Giuseppe, Foà, R., Laurenti, Luca (ORCID:0000-0002-8327-1396), Laurenti, Luca, Tarnani, Michela, Nichele, I, Ciolli, S, Cortelezzi, A, Forconi, F, Rossi, D, Mauro, Fr, D'Arena, G, Del Poeta, G, Montanaro, M, Morabito, F, Musolino, C, Callea, V, Falchi, L, Tedeschi, A, Ambrosetti, A, Gaidano, G, Leone, Giuseppe, Foà, R., and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

Although the coexistence of chronic lymphocytic leukemia (CLL) and myeloproliferative neoplasms (MPN) has been sporadically reported in the literature, no systematic studies on this disease association are available. We retrospectively analyzed 46 patients affected by CLL/MPN referred by 15 Italian GIMEMA centers. The aim of this retrospective multicenter study was to define the following: clinico-biological characteristics, possible familiarity, clinical course of both diseases, and influence of MPN chemotherapy on the course of CLL. Among 46 patients, 30 patients were males, 16 patients were females; median age was 71 years. Only one case had familiar CLL. Myeloproliferative disorders consisted of essential thrombocytemia in 18 cases, polycythemia vera in 10 cases, chronic myeloid leukemia in 9 cases, primary myelofibrosis in 6 cases, and MPN/myelodysplastic syndrome in 3 cases. The lymphoproliferative disorder was diagnosed as monoclonal B-cell lymphocytosis in 8 patients and as Binet Stage A CLL in 38 patients. After a median follow-up of 49 months, 9 patients experienced progressive CLL and only 6 patients required treatment after a median of 57.5 months. The biological profile confirmed a subset of low-risk CLL. Twenty patients received chemotherapy for MPN without influence on the course of CLL: lymphocyte counts remained unchanged after 3, 6, and 12 months of treatment. This series is the largest so far reported in literature. The diagnosis of concomitant CLL/MPN is a rare event and lymphoproliferative disorders present a clinical indolent course with a low-risk biological profile. MPN therapy does not interfere with the prognosis of patients with CLL.

Published
2011

41. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.

Author

Mauro, F. R., primary, Ciolli, S., additional, Di Raimondo, F., additional, Del Poeta, G., additional, Forconi, F., additional, Cuneo, A., additional, Cortellezzi, A., additional, Nobile, F., additional, Brugiatelli, M., additional, Massaia, M., additional, Molica, S., additional, Trentin, L., additional, Rizzi, R., additional, Orsucci, L., additional, Mura, M. A., additional, Alietti, A., additional, Runggaldier, E. J., additional, Gamba, E., additional, Guarini, A., additional, and Foa, R., additional

Published
2011
Full Text
View/download PDF

42. INTERFERON ALFA-2A AS COMPARED WITH CONVENTIONAL CHEMOTHERAPY FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

Author

Tura, S, Baccarani, M, Zuffa, E, Russo, D, Zaccaria, A, Fiacchini, M, Testoni, N, Zamagni, M, Martinelli, G, Damiani, D, Michieli, M, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Alimena, G, Mandelli, F, Leoni, P, Danieli, G, Nosari, A, Decataldo, F, Majolino, I, Caronia, F, Liberati, A, Grignani, F, Tabilio, A, Martelli, M, Paolino, F, Resegotti, L, Ditucci, A, Broccia, G, Leoni, F, Ciolli, S, Luciano, L, Rotoli, B, Perricone, R, Cajozzo, A, Montuoro, A, Delaurenzi, A, Volpe, E, Demilio, A, Battista, R, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Lombardo, M, Torlontano, G, Landolfi, R, Leone, G, Delfini, C, Sparaventi, G, Papineschi, F, Spremolla, G, Risso, M, Marmont, A, Dini, D, Diprisco, U, Mangoni, L, Rizzoli, V, Girino, M, Ascari, E, Bodenizza, C, Carotenuto, M, Difrancesco, A, Quaglino, D, Nardelli, S, Ciccone, F, Miraglia, E, Debiase, R, Gallo, E, Pileri, A, Rambaldi, A, Barbui, T, Morandi, S, Bianchini, E, Derosa, C, Cimino, R, Ronca, F, Nobile, F, Cantonetti, M, Papa, G, Gallamini, A, Buffa, F, Musolino, C, Squadrito, G, Capaldi, A, Giovannelli, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Gentilini, I, Coser, P, Guglielmo, P, Cacciola, E, Pizzuti, M, Ricciuti, F, Fanin, R, Criscuolo, D, and Montefusco, E

Subjects
Settore MED/06 - Oncologia Medica, CHRONIC MYELOGENOUS LEUKEMIA, BONE-MARROW TRANSPLANTATION, THERAPY, Settore MED/15 - Malattie del Sangue
Published
1994

43. The role of haematopoietic growth factors in the treatment of myelodysplastic syndromes

Author

Rossi Ferrini P, VALERIA SANTINI, Ciolli S, Grossi A, Leoni F, Rafanelli D, and Am, Vannucchi

Subjects
Stem Cell Factor, Myelodysplastic Syndromes, Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Humans, Interleukin-3, Hematopoietic Cell Growth Factors, Erythropoietin, Recombinant Proteins, Aged
Published
1993

44. PROGNOSTIC FACTORS IN CHRONIC MYELOID-LEUKEMIA - RELATIONSHIP WITH INTERFERON AND BONE-MARROW TRANSPLANTATION

Author

Tura, S, Russo, D, Fanin, R, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Silvestri, F, Virgolini, L, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Liberati, A, Tabilio, A, Martelli, M, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, and Ascari, E

Subjects
CHRONIC MYELOID LEUKEMIA, PROGNOSIS, INTERFERON Addresses, Settore MED/06 - Oncologia Medica, BONE MARROW TRANSPLANTATION, Settore MED/15 - Malattie del Sangue
Published
1993

45. KARYOTYPIC CONVERSION BY INTERFERON AS PREPARATIVE TREATMENT FOR AUTOLOGOUS BMT IN PH POSITIVE CML

Author

Gobbi, M, Tura, S, Russo, D, Zuffa, E, Patriarca, F, Fiacchini, M, Baccarani, M, Montefusco, E, Meloni, G, Mandelli, F, Zamagni, M, Testoni, N, Zaccaria, A, Fanin, R, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Bodenizza, C, Carotenuto, M, Rotondo, G, Ambrosetti, A, Perona, G, Majolino, I, Caronia, F, Luciano, L, Rotoli, B, Morra, E, Bernasconi, C, Rambaldi, A, Barbui, T, Ronco, F, Nobile, F, Leoni, P, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Gentilini, I, Coser, P, Dini, D, Diprisco, U, Papineschi, F, Spremolla, G, Liberati, A, Grignani, G, Tabilio, A, Martelli, M, Pardini, S, Longinotti, M, Mangoni, L, Rizzoli, V, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Leoni, F, Ciolli, S, Cantonetti, M, Papa, G, Landolfi, R, Leone, G, Gallo, E, Pileri, A, Zagonel, V, Pinto, A, Volpe, E, Difrancesco, A, Quaglino, D, Avanzini, P, Gobbi, F, Paolino, F, Resegotti, L, Saglio, G, Camaschella, C, Mazza, U, Pinotti, G, Venco, G, Capucci, A, Izzi, T, Morandi, S, Bianchini, E, Scapoli, G, Monaco, M, Pizzuti, M, Ricciuti, F, Capaldi, A, and Giovannelli, E

Subjects
INTERFERON, AUTOLOGOUS BMT, Settore MED/06 - Oncologia Medica, KARYOTYPIC CONVERSION, Settore MED/15 - Malattie del Sangue, PH+CML
Published
1993

46. TREATMENT OF PH-POSITIVE CHRONIC MYELOID-LEUKEMIA WITH ALPHA-INTERFERON (ROFERON-A) - THE ITALIAN COOPERATIVE STUDY-GROUP EXPERIENCE

Author

Tura, S, Russo, D, Zuffa, E, Fanin, R, Patriarca, F, Fiacchini, M, Baccarani, M, Testoni, N, Zamagni, M, Zaccaria, A, Montefusco, E, Alimena, G, Meloni, G, Mandelli, F, Damiani, D, Michieli, M, Criscuolo, D, Fowst, C, Holdener, E, Specchia, G, Liso, V, Morra, E, Bernasconi, C, Demilio, A, Battista, R, Ditucci, A, Broccia, G, Maiolino, I, Caronia, F, Luciano, L, Rotoli, B, Leoni, P, Danieli, G, Bodenizza, C, Carotenuto, M, Rotondo, S, Nosari, A, Decataldo, F, Montuoro, A, Delaurenzi, A, Camillo, S, Liberati, A, Grignani, F, Tabilio, A, Rambaldi, A, Barbui, T, Leoni, F, Ciolli, S, Ronca, F, Nobile, F, Paolino, F, Resegotti, L, Papineschi, F, Spremolla, G, Landolfi, R, Leone, G, Volpe, E, Mangoni, L, Rizzoli, V, Capucci, A, Izzi, T, Scapoli, G, Castoldi, G, Gentilini, I, Coser, P, Gallo, E, Pileri, A, Cantonetti, M, Papa, G, Dini, D, Diprisco, U, Morandi, S, Bianchini, E, Pinotti, G, Venco, A, Zagonel, V, Pinto, A, Capaldi, A, Giovannelli, E, Pizzuti, M, Ricciuti, F, Ambrosetti, A, Perona, G, Perricone, R, Cajozzo, A, Lombardo, M, Torlontano, G, Delfini, C, Lucarelli, G, Girino, M, Ascari, E, Risso, M, Damasio, E, Martino, S, Pardini, S, Longinotti, M, Miraglia, E, Debiase, R, Nardelli, S, Ciccone, F, Galieni, P, Dispensa, E, Abbadessa, A, Bruzzese, L, Prossomariti, L, Cimino, R, Derosa, C, Gabbas, A, Francesco, S, Gallamini, A, Difrancesco, A, Quaglino, D, Musolino, C, Squadrito, G, Avanzini, P, Gobbi, F, Nuova, A, Emilia, R, Saglio, G, Aglietta, M, Camaschella, C, Mazza, M, Guglielmo, P, Cacciola, E, and Monaco, M

Subjects
CHRONIC MYELOID LEUKEMIA, PHILADELPHIA CHROMOSOME, INTERFERON AUTOLOGOUS BONE MARROW TRANSPLANT, Settore MED/06 - Oncologia Medica, Settore MED/15 - Malattie del Sangue
Published
1993

47. Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years

Author

Bandini, G., primary, Zuffa, E., additional, Rosti, G., additional, Battista, R., additional, D'Emilio, E., additional, Leoni, F., additional, Ciolli, S., additional, Barbui, T., additional, Bassan, R., additional, Todeschini, G., additional, Perona, G., additional, Scapoli, G. L., additional, Mangoni, L., additional, Morra, E., additional, Prisco, U. Di, additional, Visani, G., additional, and Tura, S., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results